Ception Therapeutics clinical trials
Acquired by Teva Pharmaceutical Industries, Ltd., Oct 14, 2011 · source ↗
The registry lists 3 studies whose lead sponsor is Ception Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 23, 2017.
- 3studies on the registry
- 0open to participants now
Before and after it joined Teva Pharmaceutical Industries, Ltd.
- First submitted before Ception Therapeutics became part of Teva Pharmaceutical Industries, Ltd.
- 3
- First submitted after Ception Therapeutics became part of Teva Pharmaceutical Industries, Ltd.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Ception Therapeutics’ studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- reslizumab2 in phase 30 open · 3
All 3 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed3100%
Over the years
- 308
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Ception Therapeutics3 studies
Something wrong with this grouping? Tell us on the Teva Pharmaceutical Industries, Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Teva Pharmaceutical Industries, Ltd. studies →
- Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic EsophagitisCompletedNCT00635089Phase 3
Sponsor listed in the registry: Ception Therapeutics · First submitted before Ception Therapeutics became part of Teva Pharmaceutical Industries, Ltd.
- Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 YearsCompletedNCT00538434Phase 2/3
Sponsor listed in the registry: Ception Therapeutics · First submitted before Ception Therapeutics became part of Teva Pharmaceutical Industries, Ltd.
- Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled AsthmaCompletedNCT00587288Phase 2
Sponsor listed in the registry: Ception Therapeutics · First submitted before Ception Therapeutics became part of Teva Pharmaceutical Industries, Ltd.